• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

SLC18A2 Gene Record

  • Summary
  • Interactions
  • Claims
  • SLC18A2 6571 Druggable Genome

    Alternate Names:

    6571
    SOLUTE CARRIER FAMILY 18 MEMBER A2
    SLC18A2
    SVAT
    SVMT
    VAT2
    VMAT2
    193001
    10935
    ENSG00000165646
    OTTHUMG00000019121
    1012
    Q05940
    Vesicular monoamine transporter 2
    BE0000118
    SYNAPTIC VESICULAR AMINE TRANSPORTER (MONOAMINE TRANSPORTER) (VESICULAR AMINE TRANSPORTER 2) (VAT2) (SOLUTE CARRIER FAMILY 18, MEMBER 2). [SOURCE:UNIPROT/SWISSPROT;ACC:Q05940]
    VMAT2_HUMAN
    SOLUTE CARRIER FAMILY 18 MEMBER 2
    SYNAPTIC VESICLE AMINE TRANSPORTER
    MONOAMINE TRANSPORTER
    Vesicular amine transporter 2
    Synaptic vesicular amine transporter
    PA325
    T48873
    BE0008661
    Q99870

    Gene Info:

    GuideToPharmacology Gene Category Name SLC18 family of vesicular amine transporters
    GuideToPharmacology Gene Category ID 193
    Human Readable Name DRUGGABLE GENOME
    Target Main Class Transporters
    Target Subclass SLC
    Transmembrane Helix Count 12
    Target Subclass SLC18
    Target Subclass MFS
    Target Class Transporters
    Target Subclass TC:2.A.1.2.29
    Gene Biotype PROTEIN_CODING
    (8 More Sources)

    Gene Categories: Category Details

    TRANSPORTER
    DRUGGABLE GENOME

    Publications:

    Biezonski et al., 2010, Effects of 3,4-methylenedioxymethamphetamine (MDMA) on serotonin transporter and vesicular monoamine transporter 2 protein and gene expression in rats: implications for MDMA neurotoxicity., J. Neurochem.
    Hansen et al., 2002, Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity., J. Pharmacol. Exp. Ther.
    Fleckenstein et al., 2007, New insights into the mechanism of action of amphetamines., Annu. Rev. Pharmacol. Toxicol.
    Sulzer et al., 1995, Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport., J. Neurosci.
    Yasumoto et al., 2009, Inhibitory effect of selective serotonin reuptake inhibitors on the vesicular monoamine transporter 2., Neurosci. Lett.
    Horton et al., 2011, meso-Transdiene analogs inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release., J. Pharmacol. Exp. Ther.
    Sulzer et al., 2005, Mechanisms of neurotransmitter release by amphetamines: a review., Prog. Neurobiol.
    Tiwari AK et al., 2013, Analysis of 34 candidate genes in bupropion and placebo remission., Int J Neuropsychopharmacol
    FORD et al., 1958, Rauwolfia toxicity in the treatment of hypertension; comparative toxicity of reserpine and alseroxylon., Postgrad Med
    Mandela et al., Reserpine-induced reduction in norepinephrine transporter function requires catecholamine storage vesicles., Neurochem. Int.
    Erickson et al., 1992, Expression cloning of a reserpine-sensitive vesicular monoamine transporter., Proc. Natl. Acad. Sci. U.S.A.
    SCHLAGEL et al., 1957, Rauwolfia hypotension. II. Action of the alseroxylon alkaloids and epinephrine on the carotid pressoreceptors., J Am Pharm Assoc Am Pharm Assoc
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Sievert et al., 2007, Specific derivatization of the vesicle monoamine transporter with novel carrier-free radioiodinated reserpine and tetrabenazine photoaffinity labels., Anal. Biochem.
    Naudon et al., 1995, Time-course of modifications elicited by reserpine on the density and mRNA synthesis of the vesicular monoamine transporter, and on the density of the membrane dopamine uptake complex., Synapse
    Fulton et al., 1976, Comparison of the effectiveness of deserpidine, reserpine, and alpha-methyltyrosine on brain biogenic amines., Fed. Proc.
    Loeffler et al., 1979, Antibody specificity studies for reserpine, its metabolites, and synthetic reserpine congeners: radioimmunoassay., J Pharm Sci
    Gros et al., 2010, Directed evolution reveals hidden properties of VMAT, a neurotransmitter transporter., J. Biol. Chem.
    Kim et al., 2009, Dopamine signaling is required for depolarization-induced slow current in cerebellar Purkinje cells., J. Neurosci.
    Goland et al., 2009, 11C-dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls., J. Nucl. Med.
    Wimalasena, 2011, Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry., Med Res Rev
    Zheng et al., 2006, Vesicular monoamine transporter 2: role as a novel target for drug development., AAPS J
    Erickson et al., 1996, Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter., Proc. Natl. Acad. Sci. U.S.A.
    Heal et al., 2013, Amphetamine, past and present--a pharmacological and clinical perspective., J. Psychopharmacol. (Oxford)
    Teng et al., 1998, Lobeline displaces [3H]dihydrotetrabenazine binding and releases [3H]dopamine from rat striatal synaptic vesicles: comparison with d-amphetamine., J. Neurochem.
    Eiden et al., 2011, VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse., Ann. N. Y. Acad. Sci.
    Henry et al., 1998, The vesicular monoamine transporter: from chromaffin granule to brain., Neurochem. Int.
    Docherty, 2008, Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA)., Br. J. Pharmacol.
    Valdivia et al., 2004, Pharmacological analysis of the mechanisms involved in the tachycardic and vasopressor responses to the antimigraine agent, isometheptene, in pithed rats., Life Sci.
    Parker et al., 1988, Comparative effects of amphetamine, phenylethylamine and related drugs on dopamine efflux, dopamine uptake and mazindol binding., J. Pharmacol. Exp. Ther.
    Gonzalez AM et al., 1994, Synaptic vesicular monoamine transporter expression: distribution and pharmacologic profile., Brain Res Mol Brain Res
    Braselmann S et al., 2006, R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation., J Pharmacol Exp Ther
    Rolf MG et al., 2015, In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib., Pharmacol Res Perspect
  • ISOMETHEPTENE   SLC18A2

    Interaction Score: 4.18

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    15094323 7751968 3129549 15955613


    Sources:
    DrugBank

  • TETRABENAZINE   SLC18A2

    Interaction Score: 4.01

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name tetrabenazine,Nitoman
    Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

    PMIDs:
    20007701 19571144 19223416 11752352 20135628 17233532


    Sources:
    TEND TdgClinicalTrial TTD DrugBank GuideToPharmacology ChemblInteractions

  • DESERPIDINE   SLC18A2

    Interaction Score: 3.34

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Synaptic vesicular amine transporter inhibitor
    Direct Interaction yes

    PMIDs:
    20176067 11134 574544 1438304 17559790 8525459


    Sources:
    DrugBank ChemblInteractions

  • VALBENAZINE TOSYLATE   SLC18A2

    Interaction Score: 3.34

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name NBI-98854
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial TTD

  • DEUTETRABENAZINE   SLC18A2

    Interaction Score: 2.51

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Inhibition
    Endogenous Drug? False
    Direct Interaction? True

    PMIDs:
    None found


    Sources:
    TTD DrugBank GuideToPharmacology

  • ALSEROXYLON   SLC18A2

    Interaction Score: 2.23

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    13505370 13438725 11752352 17139284 17016423


    Sources:
    TEND TdgClinicalTrial TTD

  • PROPYLHEXEDRINE   SLC18A2

    Interaction Score: 1.67

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18500382 15955613


    Sources:
    DrugBank

  • ALKAVERVIR   SLC18A2

    Interaction Score: 1.67

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • VALBENAZINE   SLC18A2

    Interaction Score: 1.67

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

    PMIDs:
    None found


    Sources:
    DrugBank ChemblInteractions

  • DEXTROAMPHETAMINE   SLC18A2

    Interaction Score: 1.04

    Interaction Types & Directionality:
    inducer (activating)
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name SLI 381, SPD 465,Adderall, Adderall XR, Adderall IR
    Novel drug target Established target
    Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

    PMIDs:
    7751968 15955613


    Sources:
    TdgClinicalTrial DrugBank ChemblInteractions

  • RESERPINE   SLC18A2

    Interaction Score: 0.96

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Synaptic vesicular amine transporter inhibitor
    Direct Interaction yes
    Trial Name -

    PMIDs:
    13505370 20176067 1438304 13438725 11752352 17139284 17016423 17559790 8525459


    Sources:
    TEND TdgClinicalTrial TTD DrugBank GuideToPharmacology ChemblInteractions

  • MIDOMAFETAMINE   SLC18A2

    Interaction Score: 0.95

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    20002520 11861820


    Sources:
    TTD DrugBank

  • CHEMBL126506   SLC18A2

    Interaction Score: 0.84

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    17209801 9587917 15955613


    Sources:
    DrugBank

  • LOBELINE   SLC18A2

    Interaction Score: 0.84

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Novel drug target Established target
    Trial Name Lobeline

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial TTD

  • BENZPHETAMINE HYDROCHLORIDE   SLC18A2

    Interaction Score: 0.84

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Synaptic vesicular amine transporter inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • LISDEXAMFETAMINE DIMESYLATE   SLC18A2

    Interaction Score: 0.84

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Synaptic vesicular amine transporter inhibitor
    Direct Interaction yes
    Trial Name Vyvanse

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial ChemblInteractions

  • PARA-METHOXYAMPHETAMINE   SLC18A2

    Interaction Score: 0.72

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    20002520 11861820


    Sources:
    DrugBank

  • BENZPHETAMINE   SLC18A2

    Interaction Score: 0.67

    Interaction Types & Directionality:
    inducer (activating)

    Interaction Info:

    PMIDs:
    7751968


    Sources:
    DrugBank

  • AMPHETAMINE   SLC18A2

    Interaction Score: 0.58

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name C105, levo-amphetamine sulfate
    Novel drug target Established target
    Trial Name SLI 381, SPD 465,Adderall, Adderall XR, Adderall IR

    PMIDs:
    23539642 7751968 9648873 21272013 15955613


    Sources:
    TdgClinicalTrial DrugBank

  • MAZINDOL   SLC18A2

    Interaction Score: 0.56

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7912402


    Sources:
    DrugBank

  • DEXTROAMPHETAMINE ADIPATE   SLC18A2

    Interaction Score: 0.56

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Synaptic vesicular amine transporter inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • DEXTROAMPHETAMINE SULFATE   SLC18A2

    Interaction Score: 0.56

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Synaptic vesicular amine transporter inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • EPHEDRA   SLC18A2

    Interaction Score: 0.51

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    17209801 9587917 15955613


    Sources:
    DrugBank

  • METHAMPHETAMINE   SLC18A2

    Interaction Score: 0.45

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name low dose intravenous methamphetamine
    Novel drug target Established target

    PMIDs:
    17209801 7751968 19429089 21177475 15955613


    Sources:
    TdgClinicalTrial DrugBank

  • NOMIFENSINE   SLC18A2

    Interaction Score: 0.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7912402


    Sources:
    DrugBank

  • RESCINNAMINE   SLC18A2

    Interaction Score: 0.33

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Synaptic vesicular amine transporter inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • HISTAMINE   SLC18A2

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7912402


    Sources:
    DrugBank

  • BUPROPION   SLC18A2

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22947179


    Sources:
    PharmGKB

  • SEROTONIN   SLC18A2

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7912402


    Sources:
    DrugBank

  • NOREPINEPHRINE   SLC18A2

    Interaction Score: 0.12

    Interaction Types & Directionality:
    binder

    Interaction Info:

    PMIDs:
    8643547


    Sources:
    DrugBank

  • DOPAMINE   SLC18A2

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7912402


    Sources:
    DrugBank

  • KETANSERIN   SLC18A2

    Interaction Score: 0.08

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Inhibition
    Endogenous Drug? False
    Direct Interaction? False

    PMIDs:
    None found


    Sources:
    GuideToPharmacology

  • HALOPERIDOL   SLC18A2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7912402


    Sources:
    DrugBank

  • FOSTAMATINIB   SLC18A2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    16946104 26516587


    Sources:
    DrugBank

  • Ensembl: ENSG00000165646

    • Version: 101_38

    Alternate Names:
    SLC18A2 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • TdgClinicalTrial: Q05940

    • Version: January-2014

    Alternate Names:
    SLC18A2 Gene Symbol

    Gene Info:
    Target Class Transporters
    Target Subclass TC:2.A.1.2.29

    Publications:

  • TEND: Q05940

    • Version: 01-August-2011

    Alternate Names:
    ENSG00000165646 Ensembl Gene Id
    6571 Entrez Gene Id
    SLC18A2 Gene Symbol

    Gene Info:
    Target Main Class Transporters
    Target Subclass SLC
    Transmembrane Helix Count 12

    Publications:

  • RussLampel: ENSG00000165646

    • Version: 26-July-2011

    Alternate Names:
    SLC18A2 Display Id
    SYNAPTIC VESICULAR AMINE TRANSPORTER (MONOAMINE TRANSPORTER) (VESICULAR AMINE TRANSPORTER 2) (VAT2) (SOLUTE CARRIER FAMILY 18, MEMBER 2). [SOURCE:UNIPROT/SWISSPROT;ACC:Q05940] Description
    ENSG00000165646 Ensembl Gene Id

    Gene Info:
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • GuideToPharmacology: 6571

    • Version: 29-September-2020

    Alternate Names:
    10935 HUGO Gene ID
    10935 HUGO Gene Symbol
    solute carrier family 18 member A2 HUGO Gene Name

    Gene Info:
    GuideToPharmacology Gene Category Name SLC18 family of vesicular amine transporters
    GuideToPharmacology Gene Category ID 193

    Gene Categories:
    TRANSPORTER

    Publications:

  • PharmGKB: SLC18A2

    • Version: 18-August-2020

    Alternate Names:
    PA325 PharmGKB ID

    Gene Info:

    Publications:
    Mas S et al., 2016, Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes., Pharmacogenomics J
    Tiwari AK et al., 2013, Analysis of 34 candidate genes in bupropion and placebo remission., Int J Neuropsychopharmacol

  • DrugBank: BE0008661

    • Version: 5.1.7

    Alternate Names:
    VMAT2 DrugBank Gene Name
    Q99870 UniProt Accession

    Gene Info:

    Publications:
    Heal et al., 2013, Amphetamine, past and present--a pharmacological and clinical perspective., J. Psychopharmacol. (Oxford)
    Braselmann S et al., 2006, R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation., J Pharmacol Exp Ther
    Rolf MG et al., 2015, In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib., Pharmacol Res Perspect

  • DrugBank: BE0000118

    • Version: 5.1.7

    Alternate Names:
    SLC18A2 DrugBank Gene Name
    Q05940 UniProt Accession
    6571 Entrez Gene Id

    Gene Info:

    Publications:
    Mandela et al., Reserpine-induced reduction in norepinephrine transporter function requires catecholamine storage vesicles., Neurochem. Int.
    Erickson et al., 1992, Expression cloning of a reserpine-sensitive vesicular monoamine transporter., Proc. Natl. Acad. Sci. U.S.A.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.

  • HingoraniCasas: ENSG00000165646

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000165646 Gene Symbol
    SLC18A2 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • ChemblInteractions: SVMT

    • Version: chembl_23

    Alternate Names:
    VMAT2 GENE_SYMBOL
    SLC18A2 GENE_SYMBOL
    Synaptic vesicular amine transporter UNIPROT

    Gene Info:

    Publications:

  • Pharos: SLC18A2

    • Version: 03-September-2020

    Alternate Names:
    Synaptic vesicular amine transporter Gene Name
    Q05940 UniProt ID

    Gene Info:

    Gene Categories:
    TRANSPORTER

    Publications:

  • TTD: Synaptic vesicle amine transporter

    • Version: 2020.06.01

    Alternate Names:
    SLC18A2 TTD Gene Abbreviation
    T48873 TTD Target ID

    Gene Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21